P ulmonary hypertension, defined as a mean pulmonary arterial pressure of Ͼ25 mm Hg at rest or 30 mm Hg during exercise, impedes the ejection of blood by the right ventricle and predisposes to right ventricular failure. 1 Pulmonary hypertension can develop secondary to various heart and lung diseases and can occur in a primary (or idiopathic) form. Idiopathic pulmonary arterial hypertension (IPAH) is a rare but often fatal condition without a known cure. The estimated annual incidence of IPAH is 1 to 2 cases per million in the general population, with 6% of the cases being familial. 1 The median survival is 2.8 years from the time of diagnosis, and current treatment options for IPAH are invasive, expensive, and limited. Although they benefit patients symptomatically and functionally, these treatments usually only partially reverse the pulmonary hypertension and functional impairment.
All-trans retinoic acid (ATRA), an active metabolite of vitamin A, plays important roles in cell differentiation and proliferation during development. 2 Recently, the role of retinoids in the development of cardiovascular disease has gained attention because of the ability of ATRA to suppress growth of vascular smooth muscle cells. 3, 4 In the rat carotid injury model, ATRA decreased neointimal cellularity and extracellular matrix deposition, leading to increased lumen diameter and area. [5] [6] [7] ATRA also induced favorable remodeling of the injured artery in rabbits. 8 In cultured aortic smooth muscle cells, ATRA induced apoptosis 9 and inhibited proliferation induced by serotonin, 10 platelet-derived growth factor, 11 endothelin-1, 12 and angiotensin II. 13 The suppression of smooth muscle cell proliferation by ATRA depends on retinoic acid receptors. 5, 11, 13, 14 ATRA might also have potential for the prevention and/or treatment of pulmonary hypertension. Indeed, ATRA feeding has been shown to inhibit pulmonary hypertension induced by monocrotaline in rats. 15 Furthermore, patients with more severe chronic obstructive pulmonary disease, who would be expected to have more pulmonary vascular involvement, have decreased levels of plasma retinol, a precursor of ATRA, compared with patients with mild chronic obstructive pulmonary disease. 16 Thus, decreased ATRA levels may predispose to increased pulmonary vascular remodeling, given the evidence that ATRA negatively regulates pulmonary artery smooth muscle cell proliferation. The relationship between retinoids and pulmonary hypertension, however, has not yet been defined.
In the present study, we tested the hypotheses that patients with IPAH have reduced retinoic acid measurements compared with control subjects and that human pulmonary artery smooth muscle cells have functional retinoic acid receptors and ATRA inhibits the growth of these cells.
Methods

Patients
Patients attending the outpatient Pulmonary Hypertension Clinic at Rhode Island Hospital (Providence) were recruited for prospective studies from January 2000 to February 2002. They were included if they had a mean pulmonary arterial pressure Ͼ25 mm Hg, had a pulmonary artery wedge pressure of Ͻ15 mm Hg, and had not received treatment for IPAH such as calcium channel blockers, prostacyclins, or endothelin receptor antagonists. Patients were excluded if they had other forms of pulmonary hypertension such as pulmonary hypertension related to connective tissue disease, portopulmonary hypertension, HIV-related pulmonary hypertension, or pulmonary hypertension secondary to interstitial lung disease, chronic obstructive lung disease, thromboembolic disease, or left heart failure. Patients were also excluded if they consumed ethanol daily, had a body mass index Ͻ20 or Ͼ30 kg/m 2 , or had a history of liver disease or abnormal liver function tests. Control subjects, matched for age and gender, were healthy, receiving no medication and having no chronic, underlying medical conditions. The Institutional Review Board at Rhode Island Hospital approved the protocol, and all participants gave written, informed consent. Samples were stored at Ϫ70°C until analyses. Control experiments showed no significant changes in retinoid levels in human plasma stored at Ϫ70°C for durations similar to those of the present study.
Hemodynamic Measurements
A pulmonary artery catheter was inserted via an internal jugular or subclavian vein under fluoroscopic guidance for measurements of right atrial, pulmonary artery, and wedge pressures; cardiac output was measured by the thermodilution technique (Cardiac Output Computer, Baxter Edwards). Cardiac index and pulmonary and systemic vascular resistances were calculated from standard hemodynamic formulas.
Measurement of Retinoids, Carotenoids, and Tocopherols in Human Plasma Samples
Retinoid levels were determined by a sensitive method combining high-performance liquid chromatography (HPLC) and gas chromatograph-mass spectrometer (GC/MS) techniques. 17 Retinol, carotenoids, and tocopherols were analyzed by HPLC. 18 Venous blood (10 cm 3 ) was drawn from both patients and control subjects. Immediately after sampling, the blood was centrifuged, and plasma was stored at Ϫ80°C pending analyses. The HPLC peak of retinoic acid was eluted at 7 minutes, collected, evaporated under N 2 , and derivatized before the GC/MS analysis. The detection limit of this method was 0.1 pg retinoid acid.
Pulmonary Artery Smooth Muscle Cells
Human pulmonary artery smooth muscle cells (Cell Applications) were used for experiments after 3 to 6 passages in cell culture. Cells were treated with ATRA dissolved in dimethyl sulfoxide, and the same amount of dimethyl sulfoxide (0.02% final) was also added in the untreated controls.
Reverse-Transcription Polymerase Chain Reaction
To determine whether different retinoid receptors are expressed in human pulmonary artery smooth muscle cells, total RNA was extracted, and reverse-transcription polymerase chain reaction (RT-PCR) analyses were performed as previously described. 19 PCR primers for human RAR␣ were 5Ј primer, 5Ј-ACC CCC TCT ACC CCG CAT CTA CAA G-3Ј, and 3Ј primer, 5Ј-CAT GCC CAC TTC AAA GCA CTT CTG C-3Ј, with expected PCR products of 201 bp 20, 21 ; for RAR␤, 5Ј-AGG AGA CTT CGA AGC AAG-3Ј and 5Ј-GTC AAG GGT TCA TGT CCT TC-3Ј with 752 bp 21 ; for RAR␥, 5Ј-TTC GAG ATG CTG AGC CCT AGC TTC C-3Ј and 5Ј-CAT GCC CAC TTC AAA GCA CTT CTG-3Ј with 327 bp 21 ; for RXR␣, 5Ј-TTC GCT AAG CTC TTG CTC-3Ј and 5Ј-ATA AGG AAG GTG TCA ATG GG-3Ј with 93 bp 22 ; for RXR␤, 5Ј-ATT AAC TCA ACA GTG TCA CTC CC-3Ј and 5Ј-TTA GTC ACA GGG TCA TTT GG-3Ј with 510 bp 23 ; and for RXR␥, 5Ј-AGC TAC ACA GAT ACC CCA GT-3Ј and 5Ј-CAC ATT CTG CCT CAC TCT-3Ј with 532 bp. 23 Denaturing was performed at 94°C for 45 seconds; annealing, for 45 seconds at 55°C; and polymerase reactions, for 2 minutes at 72°C. PCR primers for human GADD45A have sequences: 5Ј primer, 5Ј-ACA GAA ACT GAT GCC AAG GG-3Ј, and 3Ј primer, 5Ј-TTT TCC TTC CTG CAT GGT TC-3Ј. 24 The annealing temperature of 54°C was used.
Electrophoretic Mobility Shift Assays
To evaluate whether ATRA induces activation of DNA binding activity of different ATRA receptors in human pulmonary artery smooth muscle cells, we prepared nuclear extracts and performed binding reactions as previously described. 25 Sequences for doublestranded oligonucleotide probe for RAR and RXR are 5Ј-TCG AGG GTA GGG TTC ACC GAA AGT TCA CTC G-3Ј and 5Ј-AGC TTC AGG TCA GAG GTC AGA GAG CT-3Ј, respectively (Santa Cruz Biotechnology).
Western Blot
Cell lysates were prepared and Western blot was performed as previously described 25 using polyclonal antibodies for phosphospecific ERK1/2 (Cell Signaling Technology), ERK1/2, and GADD45A (Santa Cruz Biotechnology). 
Gene Array Analysis
To identify the effects of ATRA on gene expression, we performed gene array analysis from human pulmonary artery smooth muscle cells treated with ATRA. Cells were treated with ATRA 2 mol/L for 20 hours, and total RNA was isolated and subjected to mRNA expression analysis using the GE Array Q Series Human Signal Transduction Pathway Finder Array (HS-008, SuperArray Bioscience Corp). RT labeling was used for synthesizing and labeling cDNA probes, and the chemiluminescent detection method was used.
Three separate experiments were performed. The complete gene table can be obtained at www.superarray.com.
Statistical Analysis
Differences between groups were considered statistically significant if PϽ0.05 as determined by Student t test.
Results
Patients
Eight IPAH patients and 8 age-and gender-matched healthy control subjects were studied. As summarized in Table 1 , ages of IPAH patients and control subjects ranged from 32 to 69 years. Patients were mostly female. Their nutritional status was considered normal, as determined by body mass index, physical examination, and baseline laboratory results such as complete blood count, liver enzymes, and a complete metabolic panel (data not shown). Functional classes were NYHA II through IV, and most of the patients had severe pulmonary hypertension, with mean pulmonary artery pressures ranging from 40 to 77 mm Hg (see Table 2 ). No patients or control subjects consumed ethanol regularly, which may deplete hepatic stores of vitamin A. 26 
Measurements of Retinoid Levels
Different isomers of retinoic acid were measured in plasma samples of normal control subjects and IPAH patients with a sensitive GC/MS technique. As shown in Table 3 , mean total retinoic acid level in age-and sex-matched control subjects was 2.95 ng/mL, whereas IPAH patients had significantly reduced levels of 2.19 ng/mL (PϽ0.05). Total retinoic acid levels in IPAH patients ranged from 1.55 to 3.04 ng/mL, with half having total retinoic acid levels of Յ2 ng/mL. Analysis of various retinoic acid isoforms revealed that the altered total retinoic acid levels in IPAH patients were due to a 40% decrease in ATRA and 13-cis retinoic acid levels (Table 3 ). Whereas the mean ATRA level of control subjects was 1.14 ng/mL, some IPAH patients had ATRA levels as low as 0.35 ng/mL. No statistically significant differences were noted in levels of 11-cis or 9-cis retinoic acid. Importantly, no significant differences were noted for plasma retinol (vitamin A) levels between IPAH patients and control subjects. Thus, differences in retinoic acid levels are not likely to be due to altered dietary intake of vitamin A. Table 4 shows the levels of various carotenoids in plasma of IPAH patients and control subjects. Although no differences in lutein, cryptoxanthin, or lycopene were noted, plasma levels of ␤-carotene, a major provitamin A carotenoid and precursor of retinoic acid, were 50% less in IPAH patients than in control subjects. We also found a 30% reduction in plasma ␣-tocopherol levels compared with control subjects (Table 4) , consistent with the occurrence of oxidative stress in IPAH patients.
Levels of Carotenoids and Tocopherols
Expression of Retinoic Acid Receptors in Human Pulmonary Artery Smooth Muscle Cells
Similar to studies on rat aortic smooth muscle cells, 11 we found that human pulmonary artery smooth muscle cells express RAR␣, RAR␤, RAR␥, RXR␣, and RXR␤, but not RXR␥, as determined by RT-PCR analysis. As shown in Figure 1A , 30 cycles of PCR generated products of 201, 752, and 327 bp, which correspond to RAR␣, RAR␤, and RAR␥, respectively. Detection of RXR required 40 cycles of PCR, which generated 93-and 510-bp products, corresponding to RXR␣ and RXR␤, respectively. However, the RXR␥ product that has an expected size of 532 bp was not generated. We performed PCR for up to 50 cycles to confirm that RXR␥ was not detectable. We also found that ATRA increased the expression of RAR␣ and RAR␤ in human pulmonary artery smooth muscle cells ( Figure 1B) . Furthermore, ATRA induced the activation of DNA binding activities toward RAR and RXR consensus sequences ( Figure 1C ). These results indicate that human pulmonary artery smooth muscle cells express retinoic acid receptors and that ATRA can elicit signal transduction in these cells.
Effects of ATRA on Serotonin-Induced Cell Growth
To determine whether ATRA has inhibitory effects on human pulmonary artery smooth muscle cell growth, cells were treated with serotonin (5-HT), a known inducer of pulmonary artery smooth muscle cell proliferation. Treatment of quiescent cells with serotonin (1 mol/L) caused an 80% increase in cell number after 6 days, consistent with proliferation of these cells. ATRA (2 mol/L) completely abrogated the serotonin-induced increase in cell number ( Figure 2) . ATRA also induced a small number of apoptotic cells (10% to 15%) as monitored by comet assay. ATRA did not cause necrotic cell death as determined by Trypan blue staining.
Effects of ATRA on Serotonin-Induced ERK Activation
Phosphorylation and activation of p44/42 mitogen-activated protein kinases (ERK) have been shown to play an essential role in the growth of bovine pulmonary artery smooth muscle cells induced by serotonin. 27 In human pulmonary artery smooth muscle cells, serotonin rapidly and transiently phosphorylated ERK within 5 minutes, as determined by Western blot using a phospho-specific ERK antibody. ATRA caused partial inhibition of serotonin-induced ERK phosphorylation, whereas the specific MEK inhibitor PD98059 caused complete inhibition (Figure 3 ).
Effects of ATRA on Gene Expression
To further identify which genes might be targeted by ATRA in inhibition of cell growth, gene array analyses were performed with the GE Array Signal Transduction Pathway Finder. This array consists of 96 genes, some of which are constitutively expressed in human pulmonary artery smooth muscle cells (Figure 4) . In 3 parallel analyses, 11 genes were found to be consistently upregulated in response to ATRA. 28, 29 To confirm the enhancement of GADD45A expression (gene 36) by ATRA in human pulmonary artery smooth muscle cells, RT-PCR and Western blot experiments were performed. As shown in Figure 5A , RT-PCR using human GADD45A primers confirmed that treatment of cells with ATRA for 20 hours enhanced GADD45A mRNA expression. We also found that ATRA enhances GADD45A protein expression as determined by Western blot ( Figure 5B ). 
Effects of Plasma From IPAH Patients and Control Subjects on Cultured Human Pulmonary Smooth Muscle Cell Growth
The experiments described above demonstrated that retinoic acid can modulate growth signaling events in human pulmonary artery smooth muscle cells. Accordingly, we tested the hypothesis that plasma from IPAH patients would influence the growth of these cells. We performed experiments to examine the effects of plasma samples on quiescent human pulmonary artery smooth muscle cell growth. These experiments revealed that plasma from control subjects can serve as a potent growth factor of human pulmonary artery smooth muscle cells (Figure 6 ). Such growth-promoting ability was dramatically higher than that of FBS, which often is used to maintain these cells. On the other hand, plasma from IPAH patients exhibited limited ability to induce cell growth. Trypan blue staining did not show increases in necrotic cell death by any of these samples (data not shown).
Discussion
We found that IPAH patients have significantly diminished circulating levels of ATRA and 13-cis-retinoic acid compared with matched control subjects, consistent with the hypothesis that insufficient retinoic acid metabolites contribute to the development of IPAH. We have supported our hypothesis with studies demonstrating that human pulmonary artery smooth muscle cells constitutively express genes for the retinoic acid receptors RAR␣, RAR␤, RAR␥, RXR␣, and RXR␤ and, when stimulated by ATRA, increase expression of RAR␣ and RAR␤, as well as DNA binding activities for RAR and RXR consensus sequences. We have also shown that ATRA suppresses serotonin-induced proliferation of human pulmonary artery smooth muscle cells, possibly via mechanisms involving inhibition of ERK activation and upregulating expression of genes, including GADD45A. Although we have not established a mechanism for the reduction in circulating ATRA and 13-cis-RA levels, our findings identify possible molecular targets for ATRA inhibition of pulmonary vascular remodeling. Possible mechanisms for the reduced ATRA and 13-cis-RA levels in IPAH patients include reduced production or release related to decreased dietary intake of vitamin A, vascular changes secondary to the pulmonary hypertension, enhanced clearance or metabolism, or a combination of these factors. The decreased levels of ␣-tocopherol and ␤-carotene in the IPAH patients compared with normal subjects suggest the occurrence of oxidative stress, which could interfere with ATRA synthesis. Previous studies have demonstrated that patients with IPAH have evidence of increased lipid peroxidation 30, 31 and increased 8-hydroxy guanosine and nitrotyrosine expression associated with reduced superoxide dismutase activity. 32 Thus, oxidative injury to synthetic metabolic pathways could lead to reduced accumulation of ATRA and 13-cis-retinoic acid in the IPAH patients.
The lower circulating levels of the retinoic acid precursor ␤-carotene 33 that we observed in the IPAH patients raise the possibility that a reduced dietary intake of ␤-carotene contributed to the reductions in ATRA and 13-cis-retinoic acid levels. However, other carotenoids that we measured, including lutein, cryptoxanthin, and lycopene, were not lower in the IPAH patients. Retinoic acid levels also depend on dietary intake of vitamin A; however, the circulating level of this vitamin was not different between control subjects and IPAH patients. Furthermore, the lack of alteration in 9-cis-retinoic acid levels suggests more strongly that dysregulated metabolism of ATRA and 13-cis-RA rather than reduced dietary intake of vitamin A or ␤-carotene is responsible for the reduced ATRA levels.
If ATRA and 13-cis-RA are important in regulating pulmonary vascular remodeling, then molecular targets must be present to convey regulatory signals. Retinoic acid receptors are required for ATRA and 13-cis-RA signal transduction. Retinoids interact with nuclear receptors to translocate into the nucleus and activate transcription of target genes. The retinoic acid receptors bind both 9-cis-RA and ATRA, whereas the retinoid X receptors bind 9-cis-RA only. Although 13-cis-RA is not a direct receptor ligand, it probably isomerizes to ATRA or 9-cis-RA to interact with different receptors. Our results indicate that, similar to findings from cultured systemic vascular smooth muscle cells, 11 all RA and retinoid X receptors, except for RXR␥, are constitutively expressed in human pulmonary artery smooth muscle cells. Furthermore, we observed that DNA binding activity for RARs and RXRs was increased with ATRA treatment, suggesting a direct effect of ATRA (or possibly one of its isomers) on transcription of target genes. This indicates that the retinoic acid receptors are functional and stimulate signal transduction in human pulmonary artery smooth muscle cells and demonstrates the feasibility of human pulmonary artery smooth muscle cell regulation by retinoids.
Further evidence for the functionality of the retinoic acid signaling system in human pulmonary artery smooth muscle cells and its possible relevance to pulmonary hypertension derives from our experiments demonstrating inhibition of human pulmonary artery smooth muscle cell proliferation by ATRA. Using serotonin to induce proliferation in human pulmonary artery smooth muscle cells, 27 we showed that ATRA completely blocked the increase in cell number. However, we cannot be certain that this finding has physiological relevance, because the concentration used approaches circulating levels seen in patients Figure 5 . Effects of ATRA on GADD45A expression. A, Quiescent human pulmonary artery smooth muscle cells were treated with ATRA (2 mol/L) for 20 hours. Total RNA was subjected to RT-PCR to monitor GADD45A and G3DPH mRNA levels. Bar graph represents meanϮSEM (nϭ3) of ratio of GADD45A to G3DPH mRNA as determined by densitometry. B, Cells were treated with ATRA (2 mol/L) for durations indicated. Cell lysates were prepared and subjected to Western blot using GADD45A and tubulin antibodies. with acute promyelocytic leukemia who are undergoing therapy with ATRA and is 10 3 times higher than normal serum levels. 34 Nevertheless, our observations using pharmacological concentrations of ATRA 3 suggest a potential use of ATRA as a therapeutic agent to reduce pulmonary vascular remodeling.
In addition, although we have demonstrated that ATRA stimulates signal transduction, we have not completely identified the signal transduction pathway involved. Serotonin-induced smooth muscle cell proliferation has been shown to occur via ERK, 27 and we showed that ATRA partially inhibited phosphorylation of ERK induced by serotonin in human pulmonary artery smooth muscle cells. This indicates that ATRA, at least in part, exerts its growth-inhibitory effect via influencing the ERKdependent pathway.
To gain further insight into the possible pulmonary vascular effects of ATRA, we performed gene array analysis after exposing human pulmonary artery smooth muscle cells for 20 hours to the same concentration of ATRA that completely inhibited proliferation. Among the 11 genes that were consistently upregulated by ATRA, GADD45A appears to be a rational candidate for involvement in the smooth muscle cell growth-inhibitory effect, because it has previously been shown to promote growth arrest and apoptosis in vascular smooth muscle cells. 28, 29 We further confirmed the upregulation of GADD45A gene expression by ATRA using RT-PCR, as well as protein expression using Western blot. These experiments demonstrate that ATRA serves to regulate gene expression in human pulmonary artery smooth muscle cells and that some of its effects may be mediated via GADD45A expression, although we readily acknowledge that we have not yet conclusively established this connection and that other pathways may be involved.
We further acknowledge a number of other limitations of our design. Although we examined blood samples from patients consecutively undergoing right heart catheterization and made efforts to examine samples only from those meeting criteria for IPAH, we cannot be certain that ours is a representative sample of all such patients. Furthermore, our patient samples were obtained from central veins (via the introducing catheter), whereas the samples from normal control subjects were taken from peripheral veins. However, Craft et al 35 have reported no differences in retinol levels between venous and capillary serum samples. Also, short of experiments demonstrating that manipulations of ATRA or GADD45A in experimental models or in clinical trials affect the severity or outcomes of pulmonary hypertension, we acknowledge that we have not established pathophysiological roles for these agents. Rather, we hope that our results will serve to generate further hypotheses and to stimulate further experimentation.
Experiments on the effects of plasma from IPAH patients and control subjects on human pulmonary artery smooth muscle cell growth surprisingly showed that plasma samples from control subjects are potent growth promoters, whereas those from IPAH patients have markedly reduced ability to promote cell growth. These observations are contrary to our central hypothesis that increased retinoic acid levels suppress cell growth, because our results show that plasma from control subjects have higher levels of retinoids than IPAH patients. However, these observations do not refute our hypothesis, because these plasma samples were taken from patients who had already developed significant degree of pulmonary hypertension. It might be revealing to perform similar experiments on cell growth using plasma from patients who are in the process of developing pulmonary vascular remodeling. Furthermore, it is intriguing to hypothesize that plasma from IPAH patients might contain other cell growth suppressive or death factors that serve as defense mechanisms to reduce the degree of pulmonary vascular thickness. Identifications of such endogenous factors might help in the development of therapeutic agents to reduce pulmonary vascular remodeling. Our HPLC results demonstrate increased oxidative stress in IPAH patients, and it is possible that oxidants might serve as such growth suppressive mediators.
In conclusion, we have shown that ATRA levels are reduced in patients with IPAH and have suggested that this reduction may predispose to the development of pulmonary hypertension by permitting pulmonary vascular remodeling via proliferation of smooth muscle cells. Furthermore, we have identified possible pathways by which retinoic acids may act to inhibit human smooth muscle cell proliferation in pulmonary arteries. Further studies are necessary to delineate the pathophysiological and possible therapeutic roles of retinoic acids in pulmonary hypertension.
